Funds › Sphera Funds Management Ltd.
Sphera Funds Management Ltd.
13F for Q2 2026, filed Aug 14, 2026. 97 positions worth $766.5M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q2 2026
filed Aug 14, 2026
Reported value
$766.5M
+$136.9M (21.7%) vs Q1 2026
Positions
97
92 in Q1 2026
Top 10 share
33.3%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Sphera Funds Management Ltd. in the latest 13F quarter?
Using 13F.ai, how has Sphera Funds Management Ltd.'s portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Sphera Funds Management Ltd.'s top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries Ltd ADR | 1.50M | $50.8M | 6.6% | +31.9% | 13F ↗ |
| 2 | MLYS Mineralys Therapeutics, Inc. | 1.47M | $39.7M | 5.2% | +9.7% | 13F ↗ |
| 3 | TSEM Tower Semiconductor Ltd. | 108,265 | $28.2M | 3.7% | -25.7% | 13F ↗ |
| 4 | SNDX Syndax Pharmaceuticals, Inc. | 1.01M | $22.2M | 2.9% | +40.0% | 13F ↗ |
| 5 | BIIB Biogen Inc. | 96,626 | $20.9M | 2.7% | +4.4% | 13F ↗ |
| 6 | RARE Ultragenyx Pharmaceutical Inc. | 588,494 | $19.6M | 2.6% | -27.3% | 13F ↗ |
| 7 | BMRN BioMarin Pharmaceutical Inc. | 328,550 | $18.8M | 2.5% | +135% | 13F ↗ |
| 8 | CYTK Cytokinetics, Incorporated | 219,987 | $18.7M | 2.4% | +452% | 13F ↗ |
| 9 | BBIO BridgeBio Pharma, Inc. | 245,346 | $18.3M | 2.4% | Unchanged | 13F ↗ |
| 10 | COGT Cogent Biosciences, Inc. | 459,340 | $17.8M | 2.3% | +10.3% | 13F ↗ |
| 11 | NVMI Nova Ltd. | 25,169 | $13.7M | 1.8% | -52.8% | 13F ↗ |
| 12 | INSM Insmed Incorporated · Com Par $.01 | 118,800 | $12.7M | 1.7% | New | 13F ↗ |
| 13 | MAZE Maze Therapeutics, Inc. | 417,564 | $12.5M | 1.6% | +83.7% | 13F ↗ |
| 14 | AZN AstraZeneca PLC | 62,530 | $11.9M | 1.5% | Unchanged | 13F ↗ |
| 15 | SNY Sanofi | 269,515 | $11.5M | 1.5% | Unchanged | 13F ↗ |
| 16 | Cybin Inc | 1.62M | $10.7M | 1.4% | +64.2% | 13F ↗ |
| 17 | LLY Eli Lilly and Company | 8,040 | $9.6M | 1.3% | -11.1% | 13F ↗ |
| 18 | MDGL Madrigal Pharmaceuticals, Inc. | 17,419 | $9.4M | 1.2% | +92.7% | 13F ↗ |
| 19 | TRVI Trevi Therapeutics, Inc. | 499,029 | $9.3M | 1.2% | -13.1% | 13F ↗ |
| 20 | ACAD ACADIA Pharmaceuticals Inc. | 356,534 | $9.0M | 1.2% | +39.2% | 13F ↗ |
| 21 | CLDX Celldex Therapeutics, Inc. | 240,868 | $9.0M | 1.2% | -1.1% | 13F ↗ |
| 22 | RYTM Rhythm Pharmaceuticals, Inc. | 80,400 | $8.9M | 1.2% | New | 13F ↗ |
| 23 | ORIC Oric Pharmaceuticals, Inc. | 752,983 | $8.2M | 1.1% | +40.1% | 13F ↗ |
| 24 | LRCX Lam Research Corporation | 18,470 | $8.0M | 1.0% | New | 13F ↗ |
| 25 | AMAT Applied Materials, Inc. | 11,040 | $8.0M | 1.0% | New | 13F ↗ |
| 26 | TNGX Tango Therapeutics, Inc. | 254,250 | $7.9M | 1.0% | -26.0% | 13F ↗ |
| 27 | NVS Novartis AG · ADR | 50,000 | $7.8M | 1.0% | +35.1% | 13F ↗ |
| 28 | Solaredge Technologies Inc Convertible | 4.00M | $7.7M | 1.0% | Unchanged | 13F ↗ |
| 29 | VOR Vor Biopharma Inc. | 416,417 | $7.7M | 1.0% | +29.4% | 13F ↗ |
| 30 | ABBV AbbVie Inc. | 30,256 | $7.6M | 1.0% | Unchanged | 13F ↗ |
| 31 | MRK Merck & Company, Inc. | 58,600 | $7.5M | 1.0% | +20.6% | 13F ↗ |
| 32 | JNJ Johnson & Johnson | 28,831 | $7.3M | 1.0% | Unchanged | 13F ↗ |
| 33 | IDYA IDEAYA Biosciences, Inc. | 196,408 | $7.3M | 1.0% | New | 13F ↗ |
| 34 | IMTX Immatics N.V. | 720,057 | $7.3M | 1.0% | +3.4% | 13F ↗ |
| 35 | NVCT Nuvectis Pharma, Inc. | 382,945 | $7.0M | 0.9% | New | 13F ↗ |
| 36 | PFE Pfizer, Inc. | 286,000 | $6.9M | 0.9% | +53.8% | 13F ↗ |
| 37 | HRMY Harmony Biosciences Holdings, Inc. | 176,663 | $6.4M | 0.8% | New | 13F ↗ |
| 38 | XENE Xenon Pharmaceuticals Inc. | 105,000 | $6.3M | 0.8% | -17.3% | 13F ↗ |
| 39 | CLYM Climb Bio, Inc. | 483,747 | $6.3M | 0.8% | +15.4% | 13F ↗ |
| 40 | ZBIO Zenas BioPharma, Inc. | 230,834 | $5.9M | 0.8% | +7.7% | 13F ↗ |
| 41 | NVO Novo Nordisk A/S · ADR | 120,677 | $5.8M | 0.8% | Unchanged | 13F ↗ |
| 42 | ELVN Enliven Therapeutics, Inc. | 112,765 | $5.7M | 0.7% | -26.4% | 13F ↗ |
| 43 | PRLD Prelude Therapeutics Incorporated | 1.02M | $5.4M | 0.7% | +82.7% | 13F ↗ |
| 44 | GSK GSK plc · ADR | 102,000 | $5.3M | 0.7% | -16.4% | 13F ↗ |
| 45 | Forte Biosciences Inc | 249,693 | $5.3M | 0.7% | +35.0% | 13F ↗ |
| 46 | BIOA BioAge Labs, Inc. | 213,671 | $5.2M | 0.7% | +147% | 13F ↗ |
| 47 | SRRK Scholar Rock Holding Corporation | 94,265 | $5.2M | 0.7% | Unchanged | 13F ↗ |
| 48 | MSLE Satellos Bioscience Inc. | 652,590 | $5.1M | 0.7% | +33.4% | 13F ↗ |
| 49 | PALI Palisade Bio, Inc. | 2.26M | $4.7M | 0.6% | +30.2% | 13F ↗ |
| 50 | ELDN Eledon Pharmaceuticals, Inc. | 1.19M | $4.7M | 0.6% | -32.8% | 13F ↗ |
Showing the top 50 of 97 positions. Premium lists every position, plus puts and calls.
Changes since Q1 2026
22 new, 33 added to, 28 trimmed, 17 exited, 14 unchanged. By estimated dollars.
New positions (22)
| INSM Insmed Incorporated · Com Par $.01 | 118,800 | New | $12.7M |
| RYTM Rhythm Pharmaceuticals, Inc. | 80,400 | New | $8.9M |
| LRCX Lam Research Corporation | 18,470 | New | $8.0M |
| AMAT Applied Materials, Inc. | 11,040 | New | $8.0M |
| IDYA IDEAYA Biosciences, Inc. | 196,408 | New | $7.3M |
| NVCT Nuvectis Pharma, Inc. | 382,945 | New | $7.0M |
| HRMY Harmony Biosciences Holdings, Inc. | 176,663 | New | $6.4M |
| VST Vistra Corp. | 29,450 | New | $4.7M |
| TLN Talen Energy Corporation | 12,135 | New | $4.7M |
| Global X Fds Cloud Computng | 195,900 | New | $4.5M |
Added to (33)
| CYTK Cytokinetics, Incorporated | 219,987 | +452% | $15.3M |
| Teva Pharmaceutical Industries Ltd ADR | 1.50M | +31.9% | $12.3M |
| BMRN BioMarin Pharmaceutical Inc. | 328,550 | +135% | $10.8M |
| SNDX Syndax Pharmaceuticals, Inc. | 1.01M | +40.0% | $6.3M |
| MAZE Maze Therapeutics, Inc. | 417,564 | +83.7% | $5.7M |
| MDGL Madrigal Pharmaceuticals, Inc. | 17,419 | +92.7% | $4.5M |
| Cybin Inc | 1.62M | +64.2% | $4.2M |
| MLYS Mineralys Therapeutics, Inc. | 1.47M | +9.7% | $3.5M |
| BIOA BioAge Labs, Inc. | 213,671 | +147% | $3.1M |
| ACAD ACADIA Pharmaceuticals Inc. | 356,534 | +39.2% | $2.5M |
Trimmed (28)
| Curis Inc | 98,996 | -95.0% | -$19.8M |
| NVMI Nova Ltd. | 25,169 | -52.8% | -$15.3M |
| TSEM Tower Semiconductor Ltd. | 108,265 | -25.7% | -$9.8M |
| RARE Ultragenyx Pharmaceutical Inc. | 588,494 | -27.3% | -$7.4M |
| BHVN Biohaven Ltd. | 164,437 | -72.3% | -$6.4M |
| RVMD Revolution Medicines, Inc. | 22,400 | -59.4% | -$6.1M |
| BCRX BioCryst Pharmaceuticals, Inc. | 422,051 | -51.3% | -$4.4M |
| ORA Ormat Technologies, Inc. | 28,015 | -59.0% | -$4.4M |
| RLAY Relay Therapeutics, Inc. | 233,836 | -42.7% | -$3.3M |
| TNGX Tango Therapeutics, Inc. | 254,250 | -26.0% | -$2.8M |
Exited (17)
| Amicus Therapeutics Inc | 603,377 | Exited | -$8.7M |
| CLBT Cellebrite DI Ltd. | 631,521 | Exited | -$8.7M |
| Apellis Pharmaceuticals Inc | 214,914 | Exited | -$8.6M |
| PANW Palo Alto Networks, Inc. | 52,800 | Exited | -$8.5M |
| CAMT Camtek Ltd. | 53,020 | Exited | -$8.0M |
| Soleno Therapeutics Inc | 216,281 | Exited | -$7.2M |
| AMZN Amazon.com, Inc. | 31,940 | Exited | -$6.7M |
| AAOI Applied Optoelectronics, Inc. | 73,400 | Exited | -$6.2M |
| ENPH Enphase Energy, Inc. | 142,419 | Exited | -$5.4M |
| ZIM ZIM Integrated Shipping Services Ltd. | 105,950 | Exited | -$2.8M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer